Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- ArQule, Inc. Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions Your first question comes from the line of Mark Monane from Needham & Company. Please proceed. Mark Monane – Needham & Company Thank you, good morning, and thank you for the comprehensive review. Brian Schwartz Good morning. Mark Monane – Needham & Company Glenn...
- Earnings calls 2009-03-05
Additional Resources
- Effects of Trial Design on Participation and Costs in Clinical Trials With an Examination of Cost Analysis Methods and Data Sources
- This paper comprises a series of studies conducted as part of the Cost of Cancer Treatment Study CCTS. The specific aims include exploring theoretical issues concerning the problem of representativeness in trial design with an explicit investigation of the causes of the under-representation of older adults in clinical cancer trials;...
- White papers 2004-10-21
- FDA Clears CoFactor to Begin Second Stage of Phase II Clinical Trial for Metastatic Colorectal Cancer
- SAN DIEGO -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced that it has been granted allowance by the Food and Drug Administration FDA to begin recruiting patients for the second stage of its Phase II trial using CoFactorTM to modulate the effect of 5-fluorouracil (5-FU) for metastatic colorectal cancer. The...
- Research articles 2004-11-02
- Dendrite and Presidio join forces to provide automated clinical trial solutions - announce first customer
- MORRISTOWN, N.J.--BUSINESS WIRE--February 10, 1997-- Dendrite International, Inc. (NASDAQ/NMS:DRTE), the largest worldwide supplier of customer management solutions for complex selling environments, today announced its first implementation of an integrated software and support solution for an automated clinical trial program in collaboration with Presidio Systems, Inc., a leading supplier of...
- Research articles 1997-02-10
- Genzyme Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Our first question comes from Mark Schoenebaum of Bear Stearns. Mark Schoenebaum - Bear Stearns Okay, hey, thanks for taking my question. Great quarter, maybe I'll just use my question for David. Can you talk about the adult Myozyme trial, can you explain, there has...
- Earnings calls 2007-07-25
- Genzyme Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Our first question comes from Mark Schoenebaum of Bear Stearns. Mark Schoenebaum - Bear Stearns Thanks for taking my question. Great quarter. Maybe I will just use my question for David. Can you talk about the adult Myozyme trial? Can you explain...
- Earnings calls 2007-07-25
- Saifun Adopts Pulsic Technology Following Rigorous Trial
- Wireless News 10-16-2007 Saifun Adopts Pulsic Technology Following Rigorous Trial WIRELESS NEWS-October 16, 2007-Saifun Adopts Pulsic Technology Following Rigorous Trial C2007 10Meters - http://www.10meters.com Pulsic Limited, a provider of custom design automation for memory, announced that...
- Research articles 2007-10-16
- Application of the Development Stages of a Cluster Randomized Trial to a Framework for Evaluating Complex Health Interventions
- The objective of this white paper is to assess the extent to which the various development steps of a cluster randomized trial to optimize antibiotic use in nursing homes are represented in a recently published framework for the design and evaluation of complex health interventions. A pilot study to assess...
- White papers 2002-07-11
- Download a copy of Microwave Office for free trial. (leading edge).(Applied Wave Research Inc)
- Applied Wave Research Inc is offering an evaluation copy of Microwave Office 2002 over the Internet for a 30-day trial period. Designers can download the fully functional simulation, layout, and electromagnetic-analysis design suite at www.mwoffic Applied Wave Research Inc is offering an evaluation...
- Research articles 2001-12-06
- AT&T'S Salt Lake HFC Trial Seeks More Than Low Costs.
- AT&T Broadband & Internet Services has more up its sleeve than merely another fiber-technology test with the trial of a new hybrid fiber-coaxial design in Salt Lake City this fall. If all goes according to the expectations of at least ...
- Research articles 1999-07-12
- Theratechnologies Receives Special Protocol Assessment From FDA for Second Pivotal Phase 3 Trial With TH9507.
- MONTREAL, QUEBEC, Aug 23, 2006 CCNMatthews via COMTEX -- Theratechnologies (TSX:TH) today announced a Special Protocol Assessment SPA from the U. S. Food and Drug Administration for the design of its second pivotal Phase 3 trial evaluating TH9507 MONTREAL, QUEBEC, Aug 23, 2006 CCNMatthews via COMTEX...
- Research articles 2006-08-23
- New trial denied in GM seat design safety case.(Neighbor)
- Byline: Tony Gordon A Zion woman paralyzed in a 1998 auto crash in Libertyville lost an effort to win a new trial last week in Lake County Circuit Court. Jennifer Andrade sued General Motors claiming that the seat design in her 1998...
- Research articles 2001-04-05
- New trial denied in GM seat-design safety case.(Neighbor)
- Byline: Tony Gordon Daily Herald Staff Writer A Zion woman paralyzed in a 1998 auto crash in Libertyville lost an effort to win a new trial last week in Lake County Circuit Court. Jennifer Andrade sued General Motors claiming that the seat design...
- Research articles 2001-04-06
- Researcher Made False Statements Regarding Strattera Trial in Kids
- An Australian researcher wrongly told a university ethics committee that Eli Lilly's Strattera did not have a black box warning label in an application for a trial of the drug in children. At the same time, an Eli Lilly employee was paid to work on the study...
- Blog posts 2009-01-27
- Can Context Justify an Ethical Double Standard for Clinical Research in Developing Countries?
- The design of clinical research deserves special caution so as to safeguard the rights of participating individuals. The paper depicts that a breach in the consensus of how to apply these ethical standards to research in developing countries helped to reduce maternal to child transmission of HIV-1. The design of...
- White papers 2005-07-26
- Silver Spring-based Optimus Corp. to design and test new system for
- Silver Spring-based Optimus Corp., a provider of information technology consulting, software design and development and public safety products, has been selected to design and test a new handheld system for collecting cancer drug trial data. The Clinical Trial Data Collection System is funded by a Small Business Innovative Research grant...
- Research articles 2003-10-21
- Simcere Shows Positive Data from Cancer Drug Trial
- ChinaBio Today submits: Simcere Pharma SCR reported that interim results from a Phase IV trial of its patented anti-cancer drug Endu showed the drug displayed both safety and efficacy. The data were in line with Endu’s Phase III trial. An anti-angiogenesis drug, Endu is a modified version of recombinant...
- External links 2008-09-03
- Nabi Biopharmaceuticals Q3 2008 Earnings Call Transcript
- Question-and-Answer Session Operator Operator instructions Your first question comes from the line of Richard Mansouri with DCM Fund. Please proceed. Richard Mansouri – DCM Fund Hi, yes. Thank you. Just a few questions. The cash and investments that you guys have. What exactly is it invested in....
- Earnings calls 2008-11-20
- LAMPS PLUS WINS JURY TRIAL OVER INFRINGEMENT OF TREE TORCHIERE PATENT.(Brief Article)
- DALLAS-A federal jury here handed down a verdict of willful patent infringement against Patrick S. Dolan, Design Trends LLC and Craftmade International Inc. At issue were three-in-one torchieres, for which Lamps Plus holds utility and design patents. In the trial, held...
- Research articles 2003-12-08
- MethylGene Initiates Second Phase I Clinical Trial With MGCD265, A Multi-Targeted (c-Met) Kinase Inhibitor in Patients With Solid Tumors
- MethylGene Inc. (TSX: MYG), today announced the dosing of the first patient in a Phase I clinical trial evaluating MGCD265 in solid tumors (Trial 101). This is the second Phase I trial with the compound which is being evaluated on different dosing schedules. In this dose-escalating Phase I trial...
- Research articles 2008-06-12
- << Previous
- page 1 of 1
- Next >>
